StreetInsider.com News Articles

Form 144 Moderna, Inc. Filed by: Hoge Stephen

Mon, 15 Jun 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260615/26646015.html

Form 144 Moderna, Inc. Filed by: Hoge Stephen

Mon, 15 Jun 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260615/26646015.html

Moderna and Oxford receive UK authorization for Lynch syndrome cancer vaccine trial

Mon, 08 Jun 2026 19:01:13 -0400

Moderna Inc. (NASDAQ: MRNA) and the University of Oxford received authorization from the UK's Medicines and Healthcare products Regulatory Agency to begin a Phase 1/2 study of an investigational mRNA cancer vaccine for people with Lynch syndrome.

The trial, called INTERCEPT-Lynch, will test mRNA-4194, Moderna's investigational vaccine designed to generate immune responses against targets associated with early cancer development in people with Lynch syndrome. This represents Moderna's first investigational cancer prevention program.

Lynch syndrome is an inherited condition affecting approximately 1 in 300 people that increases cancer risk up to 80% over a lifetime. The condition is caused by alterations in genes

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Mon, 08 Jun 2026 19:01:00 -0400

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%^[1]

The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention

OXFORD, UK AND CAMBRIDGE, MA / ACCESS Newswire / June 8, 2026 / The University of Oxford and Moderna, Inc. (NASDAQ:MRNA) today announced a Phase 1/2 study of mRNA-4194, Moderna's investigational mRNA-based cancer vaccine for Lynch Syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Mon, 08 Jun 2026 19:01:00 -0400

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%^[1]

The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention

Form 4 Moderna, Inc. For: Jun 04 Filed by: Klinger Shannon Thyme

Mon, 08 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260608/26617887.html

Form 4 Moderna, Inc. For: Jun 04 Filed by: Klinger Shannon Thyme

Mon, 08 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260608/26617887.html

Form 4 Moderna, Inc. For: Jun 05 Filed by: Mock James M

Mon, 08 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260608/26617812.html

Form 4 Moderna, Inc. For: Jun 05 Filed by: Mock James M

Mon, 08 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260608/26617812.html

Form 144 Moderna, Inc. Filed by: Klinger Shannon Thyme

Thu, 04 Jun 2026 13:27:00 -0400

si-local-file:///var/storage/secattach/20260604/26604716.html

Form 144 Moderna, Inc. Filed by: Klinger Shannon Thyme

Thu, 04 Jun 2026 13:27:00 -0400

si-local-file:///var/storage/secattach/20260604/26604716.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Mock James M

Wed, 03 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26599210.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Mock James M

Wed, 03 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26599210.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Klinger Shannon Thyme

Wed, 03 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260603/26599153.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Klinger Shannon Thyme

Wed, 03 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260603/26599153.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Hoge Stephen

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599072.html

Form 4 Moderna, Inc. For: Jun 01 Filed by: Hoge Stephen

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599072.html

Moderna (MRNA) sees strong intraday gains

Wed, 03 Jun 2026 14:14:41 -0400

Moderna (NASDAQ: MRNA) is seeing strong intraday gains

shares +6.6%
it is unclear the driver

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion